Results 21 to 30 of about 35,072 (188)

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis

Bioengineering, 2022
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness.
Michael Benzaquen, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga, Kristine Heidemeyer   +7 more
doaj   +1 more source

Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.

Gastroenterology, 2022
BACKGROUND & AIMS SERENE UC evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis (UC).
J. Panés, J. Colombel, G. D'Haens, S. Schreiber, R. Panaccione, L. Peyrin-Biroulet, E. Loftus, S. Danese, S. Tanida, Y. Okuyama, E. Louis, A. Armuzzi, M. Ferrante, H. Vogelsang, T. Hibi, M. Watanabe, J. Lefebvre, T. Finney-Hayward, Y. S. Gonzalez, T. Doan, N. Mostafa, Kimitoshi Ikeda, W. Xie, B. Huang, J. Petersson, J. Kalabic, A. Robinson, W. Sandborn   +27 more
semanticscholar   +1 more source

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

RMD Open, 2020
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligible ...
Grégoire Cormier, Benoit Le Goff, Emmanuelle Dernis, Philippe Goupille, Aleth Perdriger, Theo Rispens, David Ternant, Gilles Paintaud, Emilie Ducourau, Marine Samain, Fabienne Le Guilchard, Lucia Andras, Eric Lespessailles, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Annick de Vries, Eric Piver, Céline Desvignes, Hervé Watier, Denis Mulleman   +20 more
doaj   +1 more source

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG, Sushan LI, Sha LV, Zhao HUANG, Zhe LIU, Fuqiu LI   +5 more
doaj   +1 more source

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

JAMA Surgery, 2021
This randomized clinical trial assesses the efficacy and safety of adalimumab in conjunction with surgery in adults with moderate to severe hidradenitis suppurativa.
F. Bechara, M. Podda, E. Prens, B. Horváth, E. Giamarellos‐Bourboulis, A. Alavi, J. Szepietowski, J. Kirby, Z. Geng, C. Jean, G. Jemec, C. Zouboulis   +11 more
semanticscholar   +1 more source

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

New England Journal of Medicine, 2019
BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.
B. Sands, L. Peyrin-Biroulet, E. Loftus, S. Danese, J. Colombel, M. Törüner, L. Jonaitis, B. Abhyankar, Jingjing Chen, Raquel Rogers, Richard A. Lirio, J. Bornstein, S. Schreiber   +12 more
semanticscholar   +1 more source

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.

New England Journal of Medicine, 2022
BACKGROUND The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis ...
J. Smolen, E. Feist, S. Fatenejad, S. Grishin, E. Korneva, E. Nasonov, M. Samsonov, R. Fleischmann   +7 more
semanticscholar   +1 more source

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Case Reports in Gastroenterology, 2019
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki   +13 more
doaj   +1 more source

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.

Inflammatory Bowel Diseases, 2022
BACKGROUND Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, and dose escalation may aid in regaining clinical benefit.
E. Savelkoul, P. Thomas, L. Derikx, N. den Broeder, T. Römkens, F. Hoentjen   +5 more
semanticscholar   +1 more source

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

Clinical and Translational Science, 2020
This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis ...
Xiaoliang Ding, Ruifang Zhu, Jian Wu, Ling Xue, Meihua Gu, Liyan Miao   +5 more
doaj   +1 more source